Screener
Crinetics Pharmaceuticals CRNX Business Segments — Cost of product revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Collaboration and license revenue | 428 | 361 |
| Total revenue | 10,734 | 361 |
| Operating expenses: | ||
| Cost of product revenue | 200 | — |
| Research and development | 100,081 | 76,240 |
| Selling, general and administrative | 50,831 | 35,526 |
| Total operating expenses | 151,112 | 111,766 |
| Loss from operations | (140,378) | (111,405) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's business segments — cost of product revenue?
- Crinetics Pharmaceuticals (CRNX) reported business segments — cost of product revenue of $200K in Q1 2026.
- What does business segments — cost of product revenue mean?
- This metric captures the direct costs associated with producing and delivering the pharmaceutical products sold by the segment. It includes expenses such as manufacturing, packaging, and logistics required to bring products to market. Tracking this helps evaluate the gross margin efficiency of the company's commercialized portfolio.
Ask your AI about Crinetics Pharmaceuticals's business segments — cost of product revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude